Develops clinical-stage therapies for cancer treatment. Advances SNDX-5613 for MLL-rearranged (MLLr) and NPM1c acute myeloid leukemia (AML). Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 9.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 34% of them.
Analysts' average target sits 104% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 37% below its peak. The market has trimmed its expectations for the company.
Sales run at $172.4M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 21 buys and 10 sells. Management buying with its own money is usually read as a good sign.
A loss of $285.4M against $172.4M in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, SNDX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SNDX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (34/100) says the stock isn’t cheap.